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Abstract
Although an inflammatory microenvironment is required for successful implantation, 
an inflammatory overreaction is one of the causes of unexplained recurrent pregnancy 
losses (uRPL). Prostaglandin E2 (PGE2) plays a pivotal role in regulating immune balance 
during early pregnancy, and it can stimulate inflammatory reactions via prostaglandin 
E2 receptor 3 (EP3). However, the role of PGE2 receptor signaling in the uRPL 
remains unknown. We aimed to investigate whether EP3 signaling is involved in the 
mechanism of uRPL. Via immunohistochemistry we could show that the expression of 
cyclooxygenase-2, EP3 and G protein alpha inhibitor 1 (Gi1) was enhanced in the decidua 
of the uRPL group in comparison to the control group in first-trimester placentas.  
In vitro, we demonstrated that sulprostone (an EP1/EP3 agonist) inhibited the secretion 
of beta-hCG and progesterone in JEG-3 cells and the secretion of beta-hCG in  
HTR-8/SVneo cells while it induced the expression of plasminogen activator inhibitor 
type 1 in JEG-3 cells. In addition, PGE2/sulprostone was able to stimulate the expression 
of Gi1, phosphorylated-extracellular signal-regulated kinases 1/2 (p-ERK1/2) and p53. 
L-798,106 (an EP3-specific antagonist) suppressed the expression of EP3 and p-ERK1/2 
without affecting the secretion of beta-hCG. Elevated activation of EP3 signaling 
in first-trimester placentas plays an important role in regulating the inflammatory 
microenvironment, the hormone secretion of extravillous trophoblasts and the 
remodeling of extracellular matrix in the fetal-maternal interface. L-798,106 might  
be a ‘potential therapeutic candidate’ for the treatment of uRPL.
Introduction
Recurrent pregnancy losses (RPL) are defined as two or 
more consecutive failed pregnancies before the 20th 
week of pregnancy according to the Practice Committee 
of the American Society for Reproductive Medicine (1). 
RPL affects 1% of all women worldwide (2), and only 
a minority can be explained by particular causative 
factors, including genetic abnormalities, structural 
abnormalities, infection, endocrine abnormalities, 
immune dysfunction and thrombophilic disorders (1). 
Up to 50% of RPL cases are classified as unexplained RPL 
(uRPL). Abnormal inflammation in the fetal-maternal 
interface and unbalanced extracellular matrix (ECM) 
remodeling are considered as key factors contributing 
to uRPL (3).
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Prostaglandin E2 (PGE2) has long been known as a 
potentiator of inflammation (4) and is the major fraction 
of prostaglandins produced by the placenta (5). PGE2 can 
regulate the balance between Th1 and Th2 cell responses 
(6), modulate chemokine production (6) and suppress 
lymphocyte alloreactivity of decidual cells during early 
gestation (7). Th1/Th2 cell ratios are higher in women with 
uRPL compared to controls with healthy pregnancies (8). 
The prostaglandin E1 analog (Misoprostol) and the PGE2 
analog (Sulprostone) have been proven to be effective 
drugs for pregnancy termination (9, 10). PGE2 has been 
demonstrated to be upregulated in cervical ovulatory 
mucus (11) and the endometrium (12, 13) of women with 
uRPL compared to controls with healthy pregnancies 
during implantation. Therefore, increased expression 
of PGE2 might be a disadvantage for implantation, 
placentation and maintenance of pregnancy.
Arachidonic acid is metabolized by cyclooxygenase-1 
and cyclooxygenase-2 (COX-2) into prostaglandin H2 
(PGH2), which is converted into multiple prostaglandins 
including PGE2 (14). As a rate-limiting enzyme that 
catalyzes the synthesis of PGE2, COX-2 is localized in 
the endometrium throughout the menstrual cycle and 
during early pregnancy (15). However, results of COX-2 
expression in uRPL patients are contradictory.
PGE2 can combine with both nuclear receptors 
and membrane receptors. Previous studies of our group 
analyzed the expression of nuclear receptors in the 
placenta of spontaneous miscarried and RPL patients (16, 
17, 18, 19, 20, 21). However, little is known about the 
expression of membrane receptors of PGE2 in the placenta 
of women with uRPL. The effects of PGE2 are mainly 
facilitated by specific membrane-bound G protein-
coupled EP receptors (EP1–EP4) with various signaling 
pathways: EP1 is coupled to the G protein alpha q (Gq) 
to mobilize intracellular Ca2+, EP2 and EP4 are coupled to 
the G protein alpha stimulator (Gs) to stimulate adenylyl 
cyclase, and EP3 is mainly coupled to the G protein 
alpha inhibitor (Gi) to inhibit adenylyl cyclase (22). All 
four membrane receptors of PGE2 are expressed by the 
placenta and fetal membranes, and only EP3 is intensely 
localized in the membrane of syncytiotrophoblast in 
the placenta of women in labor (23). This indicates that 
EP3 may have an influence on trophoblast invasion and 
placentation. The expression of COX-2 and EP3 has been 
proven to be elevated in the placenta of a rat model for 
ischemia-reperfusion injury (24). PGE2 triggers mast cell 
activation via an EP3-Gi/o-Ca
2+ influx/phosphatidyl-3-
kinase signaling pathway, which contributes to vascular 
permeability and consequent edema formation in mice (4). 
However, no previous studies exist about the expression 
of EP3 in the placenta of uRPL patients, as well as the 
possible signal processes of EP3 in normal pregnancy and 
uRPL during the first trimester of pregnancy.
In addition, PGE2 binding with EP1/EP3 receptor can 
induce the production of plasminogen activator inhibitor 
type 1 (PAI-1) in cardiac fibroblasts (25). PAI-1 levels in 
the plasma are increased in RPL patients in comparison 
to women with healthy pregnancies (26). Among all the 
thrombophilic genes, PAI-1-675 4G/5G polymorphism 
is one of the most frequently analyzed PAI-1 genetic 
variants, although the contribution of PAI-1-675 4G/5G 
to uRPL is conflicting (27). 
We hypothesized that EP3 signaling may be an essential 
pathway in the mechanism of uRPL. Our study group aimed 
to analyze the main proteins’ expression of EP3 signaling 
in the placentas of first-trimester pregnancies with uRPL 
immunohistochemically. Additionally, we studied the 
effects of PGE2, an EP1/EP3 agonist (sulprostone) and an 
EP3 antagonist (L-798,106) on the function of trophoblast 
cells by using the choriocarcinoma cell line JEG-3 and the 
human trophoblast-derived cells HTR-8/SVneo in vitro.
Materials and methods
Placental tissue samples
The study was approved by the ethical committee of 
the Medical Faculty, Ludwig-Maximilian-University of 
Munich (Number of approval: 337-06) and informed 
consent was obtained from each patient in written form. 
Samples and clinical information were anonymized and 
encoded for statistical workup.
We analyzed placenta tissues of 19 patients with a 
history of more than two consecutive pregnancy losses of 
unknown causes (uRPL group) and of 19 healthy controls 
with legal pregnancy termination (control group) from 
a private practice in Munich, Germany. Exclusion 
criteria for the uRPL group, described thoroughly in 
our previous studies (28), include infectious diseases, 
uterine anomalies, endocrinological dysfunctions, 
hyperprolactinemia, hyperandrogenemia, thyroidal 
dysfunctions, autoimmunologic disorders, deficiencies 
in coagulation factors, as well as fetal and parental 
chromosomal disorders. All placentas were obtained within 
the first 24 h after diagnosis without any prior hormonal 
pretreatment. Samples were obtained by dilatation and 
evacuation without any prior pharmaceutical induction. 
These samples were fixed immediately in 4% buffered 
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formalin for 20–24 h and embedded in paraffin for further 
immunohistochemical and double immunofluorescence 
analysis (29).
Immunohistochemistry
Paraffin-embedded slides were dewaxed in xylol and 
washed in 100% ethanol. For inhibition of the endogen 
peroxidases, tissue samples were incubated in methanol 
with 3% H2O2 and rehydrated in a descending alcohol 
series. Slides were heated in a pressure cooker using 
sodium citrate buffer (pH = 6.0), containing 0.1 M citric 
acid and 0.1 M sodium citrate in distilled water. After 
cooling and washing in PBS, all slides were incubated 
with blocking solution (Reagent 1, Zytochem-Plus HRP-
Polymer-Kit (mouse/rabbit)) for 20 min to avoid non-
specific binding of the primary antibodies. The primary 
antibodies used for the experiment were anti-COX 
rabbit IgG polyclonal antibody (Sigma, SAB4502491, 
1:400 dilution), anti-EP3 rabbit IgG polyclonal antibody 
(Abcam, ab189131, 1:300 dilution) and anti-Gi1 rabbit 
IgG polyclonal antibody (Novus Biologicals, Littleton, 
CO, USA; NBP2-16558, 1:1000 dilution). The slides were 
incubated with different primary antibodies for 16 h at 
4°C. After washing, the secondary antibodies/complexes 
of the ABC detection kits (Vector Laboratories) were 
applied following the manufacturer’s protocols to detect 
reactivity. Immunostaining was visualized with the 
substrate and the chromogen-3, 3′-diaminobenzidine 
(DAB; Dako) for 1 min in case of COX-2, 2.5 min for EP3 
and 45 sec for Gi1.
Third-trimester placenta was used as a positive control 
for the immunohistochemical staining of COX-2 and Gi1 
to test antibody function and to determine an appropriate 
dilution of the antibody for staining. Colon was used as a 
positive control for EP3. Positive cells showed a brownish 
color and the negative control, as well as unstained cells, 
appeared blue (30). Negative controls were used with the 
same control tissues and were performed by replacement 
of a pre-immune serum at the same concentration as the 
primary antibody (negative control for super sensitive 
rabbit antibodies, BioGenex, California, USA).
All slides were analyzed under the microscope by two 
independent observers using a Leitz photomicroscope. 
For the light microscopy analysis, a semi-quantitative 
IRS score was used (31), which is calculated via the 
multiplication of optical staining intensity (grades: 0 = no, 
1 = weak, 2 = moderate and 3 = strong staining) and the 
percentage range of positive stained cells (0 = no staining, 
1 = ≤10% of the cells; 2 = 11–50% of the cells; 3 = 51–80% 
of the cells and 4 = ≥81% of the cells were stained for the 
antibody, respectively).
Double immunofluorescence staining
For the characterization of COX-2, EP3 and Gi1-expressing 
cells in the decidua, we applied the same paraffin-
embedded slides with double immunofluorescence 
staining. The same experimental steps were carried out 
as for immunohistochemistry until the step of blocking. 
Slides were blocked with a blocking solution (Ultra V 
Block, Lab Vision, Fremont, CA, USA) to avoid non-
specific staining and then incubated with various primary 
antibodies overnight at 4°C. Prolactin was used as a specific 
marker for stromal cells and human leukocyte antigen-G 
(HLA-G) was used as a specific marker for trophoblast cells. 
Different primary antibodies were diluted with a diluting 
medium (Dako) according to the following ratios: 1:400 
for rabbit anti-COX-2 polyclonal IgG (Sigma, SAB4502491) 
and 1:500 for mouse anti-Prolactin polyclonal IgG 
(Serotec, Kidlington, Oxfordshire, UK; MCA712), 1:300 
for rabbit anti-EP3 polyclonal IgG (Abcam, ab189131), 1: 
300 for rabbit anti-Gi1 polyclonal IgG (Novus Biologicals, 
NBP2-16558), 1:50 for mouse anti-HLA-G polyclonal IgG 
(Serotec, MCA2044). After washing, slides were incubated 
with Cy2-/Cy3-labeled antibodies (Jackson Dianova, 
Hamburg, Germany) as fluorescent secondary antibodies 
for 30 min at room temperature in darkness to avoid 
fluorescence quenching. Cy2-labeled secondary antibodies 
were at a dilution of 1:100 and Cy3-labeled antibodies were 
at a dilution of 1:500. Finally, the slides were embedded in 
mounting buffer containing 4′,6-diamino-2-phenylindole 
(DAPI, Vectastain, Vector Laboratories) for blue staining of 
the nucleus after washing and drying. Digital images were 
obtained with a digital camera system (Axiocam; Zeiss 
CF20DXC; KAPPA Messtechnik, Gleichen, Germany) and 
digitally saved.
Cell culture and cell stimulation
JEG-3 cells (ATCC HTB-36) and HTR-8/SVneo cells (ATCC 
CRL-3271) were used as trophoblast models. Both cell lines 
were cultured in RPMI 1640 medium + Gluta MAX (Gibco) 
supplemented by 10% fetal bovine serum (FCS, Gibco). 
Cells were seeded into 24-well plates for the determination 
of beta-hCG, progesterone and PAI-1 and 6-well plates for 
Western blotting. After 6–8 h, cell culture medium was 
replaced with fresh RPMI1640 with stimulation chemicals 
for the remaining 48 h, which included dimethyl sulfoxide 
(DMSO, 0.5%) as vehicle control, PGE2 (TOCRIS, Bristol, 
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International 
License.
https://doi.org/10.1530/EC-18-0106
http://www.endocrineconnections.org © 2018 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 11/29/2019 09:59:50AM
via free access
Y Ye et al. EP3 signaling is induced 
in placentas of recurrent 
miscarriage
7527:5
UK), sulprostone (TOCRIS) and L-798,106 (TOCRIS). Both 
JEG-3 (50,000 cells/ well) and HTR-8/SVneo cells (60,000 
cells/well) were incubated with PGE2, sulprostone and 
L-798,106 at different concentrations of 0.1, 1, 10, 100, 
1000 nM and 10 µM in 24-well plates.
Cell viability assay
JEG-3 cells were seeded at the density of 1.5 × 104 cells/
well in 96-well plates and were incubated with different 
concentration of PGE2 and L-798,106 for 48 h. To each 
well, 20 μg MTT (Sigma) were added for 1.5 h at 37°C. After 
removing MTT, 200 μL DMSO were added to each well 
and mixed thoroughly on the shaker for 5 min at room 
temperature. The optical density was examined at 595 nm 
using Elx800 universal Microplate Reader.
ADVIA Centaur assay
Supernatants of JEG-3 and HTR-8/SVneo cells in 24-well 
plates were collected and centrifuged (13,200 g, 10 min) 
to remove debris. The concentration of beta-hCG and 
progesterone in the supernatant was detected according 
to the manufacturer’s instructions on an ADVIA Centaur 
XP autoanalyzer (Siemens Medical Solution Diagnostics) 
as described in our previous publications (32, 33). The 
concentration of total beta-hCG was measured in a two-site 
sandwich immunoassay (ADVIA Centaur Total hCG Test; 
Siemens Medical Solutions Diagnostics). The detectable 
concentration of total beta-hCG ranges from 2.0 IU/mL 
to 1000 IU/mL. The concentration of progesterone in 
supernatants was measured by an automated quantitative 
immunoassay (ADVIA Centaur Progesterone Test; 
Siemens Medical Solutions Diagnostics) with a sensitivity 
of 0.2 ng/mL. Intraobserver and interobserver coefficients 
of variation were 9.8 and 5.8%, respectively.
PAI-1 ELISA 
PAI-1 levels in the supernatants of JEG-3 and HTR-8/SVneo 
were measured utilizing commercially available ELISA kit 
(R&D system, DSE100). A standard curve was obtained in 
parallel to each assay and results converted into ng/mL. 
The intra- and inter-assay variability was respectively 4.6 
and 8.7%.
Western blotting
Cell lysates were extracted from JEG-3 and HTR-8/SVneo 
cells with radioimmunoprecipatation assay buffer (RIPA, 
Sigma-Aldrich, R0278-50ML). For Western blotting, 20 µg 
of cell lysates were first separated in 10% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis and then 
transferred to a polyvinylidene fluoride membrane (Bio-
Rad). The membrane was blocked in 4% skim milk powder 
and then incubated with the primary antibodies for 16 h 
at room temperature. Different primary antibodies were 
used as the following: rabbit polyclonal anti-EP3 antibody 
(Abcam, ab94496, 1:500), rabbit polyclonal anti-Gi1 
antibody (Novus Biologicals, NBP2-16558, 1:500), rabbit 
polyclonal anti-phosphorylated extracellular signal-
regulated kinases (p-ERK1/2) antibody (Abcam, ab47339, 
1:500), mouse monoclonal anti-p53 antibody (Abcam, 
ab26, 1:200). Beta-actin was used as a housekeeping 
gene and mouse monoclonal anti-beta-actin antibody 
was diluted 1:1000 in 4% milk powder (Sigma, A5441). 
Afterward, the membrane was incubated with the goat-
anti-rabbit/mouse secondary antibody conjugated with 
alkaline phosphatase (1:1000 dilution, Jackson Immuno 
Research), and detected with 5-bromo-4-chloro-3′-
indolylphosphate/nitro-blue tetrazolium (BCIP/NBT)-
chromogen substrate solution (Promega). Western blots 
were scanned and quantified using the GelScan V6.0 
1D Analysis Software (SERVA, Electrophoresis GmbH, 
Heidelberg, Germany). Band intensities of EP3, Gi1, 
p-ERK1/2 and p53 were normalized with band intensities 
of beta-actin. The blots were repeated three times.
Statistical analysis
All data were analyzed with SPSS Statistics 23 software 
(IBM Corporation, Armonk, NY, USA) and are expressed as 
the mean ± s.d. Independent t-test was used to compare the 
clinical data of uRPL and control group. Mann–Whitney-U 
test was applied for evaluating IRS scores of EP3, COX-2 
and Gi1 expression in placentas of two groups. Spearman’s 
rank correlation analysis was adopted to evaluate the 
correlation between two monotonic, nonlinear variables. 
Wilcoxon test was used for the evaluation of beta-hCG, 
progesterone and PAI-1 expression levels between vehicle 
and stimulation groups. Wilcoxon test was also used for 
analyzing the band intensities of EP3, Gi1, p-ERK1/2 and 
p53. P-values <0.05 were regarded statistically significant.
Results
Clinical data of the uRPL group and control group
The mean age of the women in the uRPL group 
was 37.76 ± 4.88  years and of the control group 
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35.78 ± 5.88 years (P = 0.41). Mean gestational age of the 
uRPL group was 9.09 ± 2.17 weeks and of the control group 
9.71 ± 1.88  weeks (P = 0.66). The gravidity times were 
decreased in patients with uRPL (3.11 ± 1.08) compared to 
healthy controls (3.42 ± 1.90, P = 0.002), while the parity 
times of two groups showed no significant differences 
(0.94 ± 0.94 vs 1.63 ± 1.12, P = 0.35). Demographic and 
clinical data are illustrated in Table 1.
Expression of COX-2, EP3 and Gi1 in the placenta of 
women with uRPL and controls 
Expression of COX-2, EP3 and Gi1 was identified in the 
cytoplasm of cells in the syncytium and the decidua of 
first-trimester pregnancies in both the uRPL group and 
the control group (Fig. 1A, B, C, D, E, F, G, H, I, J, K, L, M, 
N, O, P, Q and R). A significant increase in the expression 
of COX-2 could be observed in the syncytium of the uRPL 
group in comparison to the control group (IRS 8.73 vs 
5.59; P = 0.007, Fig. 1A, B and E). COX-2 expression in the 
decidua of the uRPL group was also significantly increased 
in comparison to the control group (IRS 4.29 vs 2.00; 
P = 0.004, Fig. 1C, D and F).
Expression of both EP3 and Gi1 in the decidua was 
significantly upregulated in patients with uRPL compared 
to normal controls (Fig.  1L and R), but no significant 
changes of EP3 and Gi1 could be observed in the syncytium 
(Fig. 1K and Q). In the uRPL group, EP3-staining in the 
decidua was more intense with a mean IRS of 4.15, which is 
higher than the mean IRS of the control group (IRS = 2.22, 
P = 0.001, Fig. 1I, J and L). EP3-staining in the syncytium 
of the uRPL group was similar to the control group (IRS 
5.75 vs 6.32; P = 0.350, Fig. 1G, H and K). Gi1-staining was 
stronger in the decidua of the uRPL group compared to the 
control group (IRS 4.48 vs 2.89; P = 0.008, Fig. 1O, P and 
R). There was no significant staining difference for Gi1-
staining in the syncytium between the uRPL group and 
the control group (IRS 5.27 vs 4.47; P = 0.292, Fig. 1M, N 
and Q). Both positive and negative controls are shown in 
the Supplementary Fig. 1 (see section on supplementary 
data given at the end of this article).
Expressions of COX-2, EP3 and Gi1 were all increased 
in the decidua of patients with uRPL compared to healthy 
controls, implying that a correlation could exist between 
them. We further analyzed the correlation of each two of 
these three components in the decidua. Unfortunately, 
there was no statistically significant correlation between 
COX-2 and EP3 expression (r = −0.059; P = 0.788), neither 
for EP3 and Gi1 (r = 0.251; P = 0.261) nor for COX-2 and Gi1 
(r = 0.158, P = 0.450) in the decidua.
Localization of COX-2, EP3 and Gi1 in the decidua of 
first-trimester placentas 
As the decidua consists of maternal decidual stroma cells 
and extravillous trophoblasts, double immunofluorescence 
was used to identify COX-2, EP3 and Gi1-expressing 
cells. Prolactin was used as a marker for stromal cells 
and HLA-G as a maker for trophoblasts, respectively. 
COX-2 was co-expressed with prolactin predominantly in 
the cytoplasm of stromal cells (Fig.  2A, B and C). Both 
EP3 (Fig.  2D, E and F) and Gi1 (Fig.  2H, I and G) were 
co-expressed with HLA-G in the cytoplasm of extravillous 
trophoblasts. Gi1 was expressed especially beneath the cell 
membrane of extravillous trophoblasts (Fig.  2G). Since 
co-expression of COX-2, EP3 and Gi1 was similar in both 
the uRPL and control group, we only showed pictures of 
the uRPL group.
Influence of PGE2, sulprostone and L-798,106 on the 
expression of EP3 signaling in JEG-3 cells in vitro
In order to investigate the mechanism of the EP3 
signaling in extravillous trophoblasts of uRPL in vitro, 
JEG-3 and HTR-8/SVneo cells were used and stimulated 
with different concentrations of PGE2, EP1/EP3 agonist 
(sulprostone) and EP3 antagonist (L-798,106) for 48 h.
Firstly, the MTT assay was used to assess the viability 
of JEG-3 cells after 48 h of treatment with 0.1, 1, 10, 
100, 1000 nM and 10 µM PGE2, L-798,106 or the vehicle 
control (DMSO, 0.1%). 10 nM PGE2 and 10 nM L-798,106 
Table 1 Demographic and clinical characteristics of the study population.
Characteristic Normal pregnancy (n = 19) uRPL (n = 19) P-value (t-test)
Maternal age (years) 35.78 ± 5.88 (25–46) 37.76 ± 4.88 (30–44) 0.41
Gestational age (weeks) 9.71 ± 1.88 (6–13) 9.09 ± 2.17 (4–12) 0.66
Gravidity 3.42 ± 1.90 (1–7) 3.11 ± 1.08 (2–5) 0.002
Parity 1.63 ± 1.12 (0–4) 0.94 ± 0.94 (0–3) 0.35
Values are represented as mean ± s.d.; the range is shown in parentheses.
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Figure 1
Immunohistological analyses of COX-2, EP3 and Gi1 expression in placentas of uRPL patients (B, D, H, J, N and P) and healthy controls (A, C, G, I, M 
and O) from the first trimester were measured via IRS score. In the syncytium, the stainings of COX-2 (A and B), EP3 (G and H) and Gi1 (M and N) are 
compared between the uRPL patients and controls, which are represented as box-plots (E, K and Q). In the decidua, the expressions of COX-2  
(C and D), EP3 (I and J) and Gi1 (O and P) are increased in uRPL patients compared to controls, which are represented as box-plots (F, L and R). The 
range between the 25th and 75th percentiles is represented by the boxes with a horizontal line at the median. The bars show the 5th and 95th 
percentiles. Dots indicate values more than 1.5 box lengths from the 75th percentile. Magnification ×10 lens, scale bar = 200 µm. uRPL = unexplained 
recurrent pregnancy losses. COX-2, cyclooxygenase-2; EP3, prostaglandin E2 receptor 3; Gi1, G protein alpha inhibitor 1; uRPL, unexplained recurrent 
pregnancy losses.
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significantly increased viability of JEG-3 cells compared to 
control group (P < 0.05, data not shown).
For JEG-3 cells, the production of beta-hCG was 
suppressed from 16.33 ± 3.30 IU/mL in the vehicle to 
12.20 ± 1.76 IU/mL by 10 nM PGE2 (P = 0.046), while 
its concentration was not significantly influenced by 
0.1 nM and 1 nM PGE2 (Fig. 3A). Additionally, beta-hCG 
expression was inhibited from 16.33 ± 3.30 IU/mL in the 
vehicle to 10.19 ± 1.79 IU/mL and 10.99 ± 1.15 IU/mL 
when sulprostone concentration was 1 nM and 10 nM 
(P = 0.028, P = 0.028, respectively, Fig. 3A). However, beta-
hCG levels were not altered by L-798,106 independent of 
the concentration of 0.1, 1 or 10 nM (Fig. 3A).
Progesterone expression of JEG-3 cells was downregu-
lated by PGE2, sulprostone and L-798,106, independent of 
different concentrations (0.1, 1 and 10 nM) in comparison to 
the vehicle after 48 h (P = 0.028, each) (Fig. 3B).
PAI-1 levels were significantly altered 34% higher 
through 10 nM sulprostone than the vehicle, while no 
significant changes of PAI-1 expression were detected 
through 10 nM PGE2 and 10 nM L-798,106 (Fig. 3C).
Western blotting was utilized to access the expression 
of EP3, Gi1 and p-ERK1/2 in JEG-3 cells stimulated by PGE2 
and L-798,106, 10 nM each (Fig. 3D). The molecular weight 
of EP3 is 37 kDa and of Gi1 it is 40 kDa. EP3 expression was 
decreased by 31.8% after treatment with 10 nM L-798,106 
compared to the vehicle group (P = 0.008, Fig.  3D). Gi1 
expression was increased by 12.4% through 10 nM PGE2 
(P = 0.012, Fig. 3E). The molecular weights of p-ERK1/2 are 
44 and 42 kDa.
Figure 2
Localization of COX-2, EP3 and Gi1 is shown in the decidua of patients with uRPL. COX-2 is co-expressed with prolactin, which is a specific marker for 
stromal cells (A, B and C). EP3 is co-expressed with HLA-G, which is a specific marker for extravillous trophoblasts (D, E and F). Gi1 is co-expressed with 
HLA-G in extravillous trophoblasts (G, H and I). Co-expression of COX-2, EP3 and Gi1 is shown with →. Magnification ×63, scale bar = 20 µm. COX-2, 
cyclooxygenase-2; EP3, prostaglandin E2 receptor 3; Gi1, G protein alpha inhibitor 1; uRPL, unexplained recurrent pregnancy losses.
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JEG-3 cells were incubated with 0.5% DMSO for 1, 
2, 6, 12, 24, 48 h and the results showed there was the 
strongest expression of p-ERK1/2 after 1 h incubation 
(Supplementary Fig.  2A). After 1 h incubation, the 
expression of p-ERK1/2 was stimulated by 18.3% through 
10 nM sulprostone compared to the vehicle (P = 0.035), 
while no significant change was detected in the group 
treated with 10 nM PGE2 or L-798,106 (Fig. 3F).
Influence of PGE2, sulprostone and L-798,106 on the 
expression of EP3 signaling in HTR-8/SVneo cells 
in vitro
HTR-8/SVneo cells were incubated with PGE2, sulprostone 
and L-798,106 at a concentration of 10 nM and 100 nM, 
respectively. Beta-hCG levels of HTR-8/SVneo cells 
were downregulated through PGE2, sulprostone and 
L-798,106 for all concentrations after 48 h (P < 0.05, each) 
(Fig.  4A). Progesterone levels could not be detected in 
the supernatants of HTR-8/SVneo cells. PAI-1 levels were 
reduced 3.7% through 10 nM L-798,106 than the vehicle, 
while no significant changes of PAI-1 expression were 
detected through 10 nM sulprostone (Fig. 4B)
In Western blotting, EP3 expression was increased 
by 11.6% through 10 nM PGE2 (P = 0.011, Fig. 4C) and 
decreased by 25.9% through 10 nM L-798,106 compared 
to the vehicle (P = 0.008, Fig.  4C). Gi1 expression was 
increased by 22.5% through 10 nM sulprostone (P = 0.046, 
Fig.  4D), while no significant changes were observed 
through 10 nM PGE2. The expression of p-ERK1/2 
decreased when the incubation time with 0.5% DMSO 
is increased from 1 to 48 h and the strongest expression 
of p-ERK1/2 was after 1 h incubation (Supplementary 
Fig.  2A). The expression of p-ERK1/2 was inhibited by 
21.8% after treatment with 10 nM L-798,106 for 1 h 
compared to the vehicle group (P = 0.011, Fig.  4E).The 
molecular weight of p53 is 53 kDa, and its expression 
was stimulated by 17.0% through 10 nM PGE2 (P = 0.028, 
Fig.  4F) and by 24.5% through 10 nM sulprostone 
(P = 0.028, Fig. 4F).
Figure 3
Expression of beta-hCG, progesterone, PAI-1, EP3, Gi1, p-ERK1/2 in JEG-3 cells after incubation with PGE2, the EP1/EP3 agonist (sulprostone) and EP3 
antagonist (L-798,106). Beta-hCG, progesterone and PAI-1 expression levels were measured via ELISA (each group n = 6). EP3, Gi1, p-ERK1/2 expression 
extracted from JEG-3 cells were detected by Western blotting, following treatment with PGE2 (10 nM) and L-798,106 (10 nM) for 48 h (n = 3). All data are 
shown as mean ± s.d. and statistically significant differences (P < 0.05) between individual treatment groups and the vehicle are marked with an asterisk. 
EP3, prostaglandin E2 receptor 3; Gi1, G protein alpha inhibitor 1; PGE2, prostaglandin E2; PAI-1, plasminogen activator inhibitor; p-ERK1/2, 
phosphorylated extracellular signal-regulated kinases 1/2.
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Discussion
An increased inflammatory reaction is one of the main 
causes of uRPL (8). PGE2 plays a pivotal role in regulating 
immune balance and angiogenesis during early pregnancy 
(8), and it is able to stimulate inflammatory reactions 
via EP3 (4). The role of PGE2 receptor signaling in the 
mechanism of uRPL still remains unknown. Our group is 
the first to investigate EP3 signaling pathway in placentas 
of patients with uRPL. 
As the rate-limiting enzyme for PGE2 synthesis, 
COX-2 is expressed by human endometrial stromal cells 
(34), and it is involved in the implantation of blastocysts 
in the early pregnancy phase (35). So far, a small number 
of publications exist about COX-2 expression levels in 
uRPL, but the results are conflicting. One research group 
reported that lower expression levels of COX-2 have been 
found in the chorionic villi of women with uRPL (35), and 
another group showed the similar result in the embryo of 
mice with autoimmune-type recurrent miscarriages (36). 
Our result is in accordance with a further study group who 
found that the expression levels of COX-2 are increased 
in the endometrium of uRPL women in comparison to 
healthy controls (13). In this study, expression of PGE2 
and pro-inflammatory cytokines is also induced in the 
endometrium of women with uRPL, such as interleukin 
1beta, tumor necrosis factor alpha (TNF-alpha), interferon 
gamma (IFN-gamma) and transforming growth factor 
beta1 (TGF-beta1) (13). IL-1, TNF-alpha and IFN-gamma 
belong to Th1 cytokines, and this Th1 predominance has 
been known to be one of the immunological reasons for 
uRPL (37). In addition, TNF-alpha can induce COX-2 gene 
expression in first-trimester trophoblasts (38).
Ryantova et al. (2008) observed that PGE2 levels in the 
cervical ovulatory mucus are increased in patients with 
uRPL (11), which is mainly caused by increased levels of 
COX-2. However, the effects of PGE2 on trophoblast cells 
in vitro are contradictory. Biondi et al. (2006) proved that 
PGE2 inhibits proliferation and migration of HTR-8/SVneo 
cells by enhancing cAMP (39), while Horita et al. (2007) 
suggested that PGE2 promotes migration of HTR-8/SVneo 
cells by leukemia inhibitory factor (40). We investigated 
that PGE2 inhibited the production of beta-hCG and 
progesterone in JEG-3 cells and the production of 
beta-hCG in HTR-8/SVneo cells. Low expression levels of 
beta-hCG and progesterone in the serum have been used 
to diagnose early pregnancy losses (41, 42). Intravaginal 
PGE2 can decrease the excretion of hCG in the urine and 
Figure 4
Expression of beta-hCG (A), PAI-1 (B), EP3 (C), Gi1 (D), p-ERK1/2 (E) and p53 (F) in HTR-8/SVneo cells after incubation with PGE2, the EP1/EP3 agonist 
(sulprostone) and EP3 antagonist (L-798,106). The levels beta-hCG and PAI-1 were measured via ELISA (each group n = 6). EP3, Gi1, p-ERK1/2 and p53 
expression extracted from HTR-8/SVneo cells were detected by Western blotting, following treatment with PGE2 (10 nM), sulprostone (10 nM) and 
L-798,106 (10 nM) for 48 h (n = 3). All data are shown as mean ± s.d. and statistically significant differences (P < 0.05) between individual treatment groups 
and the vehicle are marked with an asterisk. EP3, prostaglandin E2 receptor 3; PGE2, prostaglandin E2; PAI-1, plasminogen activator inhibitor; p-ERK1/2, 
phosphorylated extracellular signal-regulated kinases 1/2.
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progesterone in the plasma (43), which is in line with our 
study that high expression levels of PGE2 in the placenta 
are detrimental to pregnancy maintenance.
Prostaglandin E2 receptors (EP1–4) are G protein-
coupled receptors that both bind and are activated by PGE2. 
Yamazaki et al. (2006) indicated that mRNA and protein 
expression of COX-2 and EP3 are increased in the placenta 
of rats after ischemia-reperfusion, which is associated with 
intrauterine growth restriction (24). In our study we could 
demonstrate that EP3 expression was mainly expressed in 
the extravillous trophoblasts and increased in extravillous 
trophoblast cells of uRPL patients compared to normal 
pregnancies in the first trimester of pregnancy. The EP3 
gene formed nine distinct mRNAs encoding at least 
eight EP3 isoforms (44), and the anti-EP3 antibody we 
used could detect the protein region within the internal 
sequence amino acids 360–409. It might partly explain 
different band signals of EP3 in JEG-3 and HTR-8/SVneo 
cells for in vitro studies. We furthermore investigated that 
sulprostone (an EP1/EP3 agonist) inhibited the secretion 
of beta-hCG and progesterone in JEG-3 cells and beta-
hCG expression in HTR-8/SVneo cells. Sulprostone, as 
a PGE2 analog, can be used for medical termination of 
early pregnancy (10). Sulprostone coupling with EP1 
or EP3 receptor may result in a reduced production of 
beta-hCG and progesterone in extravillous trophoblasts. 
Both are detrimental to blastocyst growth and pregnancy 
maintenance (45). However, Biondi et al. (2006) reported 
that PGE2 inhibited proliferation and migration of 
HTR-8/SVneo cells via EP2 and EP4 receptors instead of 
EP3 (39). In order to investigate the exhaustive 
mechanisms of membrane receptors of PGE2 in the 
placenta of uRPL, the remaining membrane receptors of 
PGE2 (EP1, EP2 and EP4) still need to be explored, among 
which the EP1 receptor represents an important receptor 
we will focus on in future investigations (46).
The activation of G protein-coupled receptors 
stimulates the activity of adenylate cyclase (AC), 
increases intracellular levels of cAMP and activates 
protein kinase A (PKA), and this cAMP/PKA signaling 
cascade is a key second messenger pathway for steroid 
biosynthesis (47). Gi inhibits AC, resulting in decreased 
levels of cAMP and therefore inhibiting activity of PKA 
(48). We found that the expression of Gi1 was mainly 
expressed in extravillous trophoblasts and upregulated 
in the decidua of women with uRPL. It suggests that the 
cAMP/PKA signaling pathway may be suppressed in the 
extravillous trophoblasts of uRPL. cAMP stimulates the 
transcription of the alpha-hCG gene expression in villous 
trophoblasts by interacting with the CREB (49). PKA can 
stimulate progesterone synthesis in the human placenta 
by phosphorylation of enzymes (50). We investigated 
that both PGE2 and sulprostone stimulated the expression 
of Gi1 and suppressed the production of beta-hCG and 
progesterone, which can be explained by the activated 
EP3/Gi1 and inhibited cAMP/PKA signaling.
Interestingly, we investigated that only sulprostone 
was able to upregulate the expression of PAI-1 in JEG-3 
cells, which is known as the main inhibitor of fibrinolysis 
(51). High plasma levels of PAI-1 and high PAI activities 
are present in women suffering from uRPL in comparison 
to healthy controls (26). PGE2 utilizes EP1/EP3 to increase 
PAI-1 levels in cardiac fibroblasts, contributing to elevated 
fibrin deposition in aortic stenosis (25). TGF-beta1 can 
induce PAI-1 gene expression by phosphorylation of 
extracellular signal-regulated kinases (ERK1/2) and p53 
(52). The expression of p53 is increased in chorionic 
villi of RPL patients compared to healthy controls (53). 
We found that sulprostone stimulated the expression of 
phosphorylated-ERK1/2 (p-ERK1/2) in JEG-3 cells and the 
expression of p53 in HTR-8/SV neo cells. Additionally, 
the expression of p-ERK1/2 was inhibited by L-798,106 
in HTR-8/SV neo cells. The activation of EP3 signaling 
induces increased expression of p-ERK1/2 and p53 in 
extravillous trophoblasts, which results in increased PAI-1 
gene expression and an imbalance of ECM degradation 
during first-trimester pregnancies. Both the in vivo 
study of Yamazaki et al. (24) and also our study suggest 
that under pathological circumstances large differences 
in EP3 expression in the placenta can be observed. In 
contrast, only small magnitude changes of EP3 and 
PAI-1 were detected in our cell culture studies. It implies 
that trophoblast cells in vitro can mimic parts of the 
in vivo environment, however it still cannot replace the 
complex physical milieu of the placenta. Therefore, 
in vivo investigations of EP3 regulation in animal models 
or observational studies in humans should be the focus 
in future.
In conclusion, we suggest that the reason for 
increased PGE2 expression in the placenta in women 
with uRPL might due to enhanced levels of COX-2 in 
stromal cells of the placenta. PGE2 in combination with 
EP3 receptor of extravillous trophoblasts induces Gi1 and 
inhibits AC activity, contributing to reduced levels of 
cAMP and inhibited activity of PKA (Fig. 5). The decreased 
cAMP/PKA signaling could suppress the production of 
beta-hCG and progesterone. At the same time, the activated 
EP3/Gi1 can stimulate p-ERK1/2 and p53, enhancing PAI-1 
gene expression (Fig. 5). Upregulation of PAI-1 can inhibit 
ECM degradation, contributing to intervillous fibrin 
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deposition in the maternal-fetal interface. These changes 
could prevent trophoblast implantation and placentation, 
causing failed pregnancy maintenance. It is still unclear 
whether the observed findings are reflective of the uRPL 
or causative of it. We explored that the EP3 antagonist 
(L-798,106) led to a downregulation of EP3 expression 
without influencing the beta-hCG expression in JEG-3 
cells. This suggests that L-798,106 might be a ‘potential 
therapeutic candidate’ for the treatment of uRPL. To 
further investigate the mechanism of uRPL, future studies 
are necessary to understand the role of the additional 
membrane receptors of PGE2 (EP1, 2 and 4) and other 
members of Gi family (Gi2 and Gi3) in the placenta.
Supplementary data
This is linked to the online version of the paper at https://doi.org/10.1530/
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Figure 5
EP3 signaling is induced in the extravillous trophoblasts of uRPL patients. Arachidonic acid is metabolized by COX-2 into PGH2, which is converted into 
multiple prostaglandins, such as PGE2 (14). PGE2 acts through different membrane receptors (EP1–4) (22). In the placenta of uRPL patients, enhanced 
levels of COX-2 might be the reason for increased PGE2 expression. PGE2 coupling with EP3 induces Gi1 and reduces cAMP, which can eventually lead to a 
downregulation of beta-hCG and progesterone and an upregulation of PAI-1. The decreased cAMP/PKA signaling inhibits the secretion of progesterone 
via PKA (50) and the transcription of beta-hCG via CREB (49). The activated EP3/Gi1 can stimulate p-ERK1/2 and p53, which eventually enhance PAI-1 
gene transcription (52). These changes could prevent trophoblast implantation and placentation, finally causing recurrent pregnancy losses. COX-2, 
cyclooxygenase-2; Gi1, G protein alpha inhibitor 1; Gq, Gprotein alpha q; Gs, G protein alpha stimulator; PAI-1, plasminogen activator inhibitor type 1; 
p-ERK1/2, phosphorylated extracellular signal-regulated kinases 1/2; PGE2, prostaglandin E2; PGH2, prostaglandin H2; PKA, protein kinase A; uRPL, 
unexplained recurrent pregnancy losses.
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